BioMarin Pharmaceutical Inc. (BMRN) entered into a binding term sheet with Ascendis Pharma A/S for a global settlement and license related to BioMarin’s C‑type natriuretic peptide patent portfolio. BioMarin will grant Ascendis a non‑exclusive, worldwide, transferable, royalty‑bearing license covering Yuviwel (TransCon CNP/navepegritide) for all current and potential indications, including achondroplasia and hypochondroplasia, and for combination use with other medicines.
In return, Ascendis will pay BioMarin a 20% royalty on annual net sales of licensed products in the U.S. and 18% on annual net sales in the EU, Brazil and South Korea, in each case from first commercial sale (retroactively, as applicable) through May 2030. The settlement provides for dismissal with prejudice of all pending patent-related proceedings between the companies worldwide, includes covenants not to challenge or sue on the relevant patents, and a mutual regulatory non‑interference clause. The term sheet is immediately binding and will remain in force even if a more detailed settlement and license agreement is not finalized by September 24, 2026.
BioMarin Pharmaceutical Inc. is entering into a definitive agreement to acquire Alesta Therapeutics B.V. via a share purchase transaction on a cash‑free, debt‑free basis. Alesta shareholders will receive an upfront cash payment of $275 million, plus up to $215 million in additional payments tied to development and regulatory milestones. Closing is targeted for the third quarter of 2026, subject to customary conditions, including a pre‑closing spinout of Alesta’s non‑ALE1 assets into a separate entity and the absence of legal orders blocking completion.
The acquisition gives BioMarin rights to ALE1, an orally active small molecule in an ongoing Phase 1/2a trial for hypophosphatasia (HPP), a rare genetic bone disease. ALE1 is positioned as a potential first oral therapy targeting the disease‑central metabolite PPi. BioMarin plans to fund the deal with cash on hand and expects the transaction, excluding the upfront consideration, to be modestly dilutive to 2026 financial results. Following closing, ALE1 will join BioMarin’s Skeletal Conditions Business Unit, supporting its strategy to expand into larger rare disease markets.
BioMarin Pharmaceutical Inc. delivered Q2 2026 total revenues of $989.7 million, up from $825.4 million in 2025, driven by VOXZOGO, PALYNZIQ and newly acquired GALAFOLD and POMBILITI + OPFOLDA. Net income fell to $44.8 million (basic and diluted EPS $0.23) from $240.5 million as operating and financing costs rose.
Higher expenses included $73.5 million of intangible asset amortization, $63.3 million of interest expense and increased SG&A tied to the $5.3 billion Amicus acquisition and related restructuring. At June 30, 2026, cash and cash equivalents were $874.0 million, total debt principal was $4.3 billion, and operating cash flow for the first half of 2026 was $388.8 million.
BioMarin Pharmaceutical Inc. reported strong top-line growth for the quarter ended June 30, 2026, with total revenues up 20% year-over-year to $990 million, driven by contributions from newly acquired GALAFOLD and POMBILITI + OPFOLDA, VOXZOGO growth, and higher PALYNZIQ sales. VOXZOGO revenue rose to $253 million, and Metabolic Conditions revenue benefited from the Amicus acquisition despite softer ALDURAZYME and timing-related government orders.
Profitability declined as GAAP net income fell to $45 million from $241 million and Non-GAAP income to $236 million from $282 million, reflecting Amicus-related integration and restructuring costs, higher amortization, and increased interest expense on new debt. Full-year 2026 guidance was raised for total revenues ($3.875–$3.925 billion), VOXZOGO ($1.0–$1.05 billion), and Non-GAAP diluted EPS ($4.90–$5.10). The company targets about $280 million GAAP cost reductions from Amicus by 2028 and gross leverage below 2.5x by mid-2027, while advancing an expanded rare-disease pipeline, including VOXZOGO label expansions and new programs, and discontinuing BMN 401.
BioMarin Pharmaceutical Inc. filed an amendment to its prior acquisition report to add full historical financial statements for Amicus Therapeutics and unaudited pro forma combined financials reflecting Amicus as a wholly owned subsidiary. The audited Amicus statements show 2025 net product sales of $634.2 million, driven by Galafold and Pombiliti + Opfolda, and a net loss of $27.1 million. Total assets were $949.9 million, including $214.0 million of cash and cash equivalents and $79.5 million of marketable securities, against long‑term debt of $392.7 million under a senior secured term loan due 2029. The notes describe Amicus’ pending cash Merger Agreement with BioMarin at $14.50 per share, its rare‑disease product portfolio, significant tax attributes, and key collaborations and obligations.
BioMarin Pharmaceutical director Athena Countouriotis reported a routine equity compensation grant. On June 2, 2026, she acquired 7,490 shares of common stock in the form of restricted stock units, with no purchase price involved. Following this award, she directly holds 21,040 common shares.
BioMarin Pharmaceutical director Timothy P. Walbert reported an equity grant of 7,490 shares of common stock on June 2, 2026. The shares were received as restricted stock units granted on that date, with no purchase price involved, reflecting stock-based compensation rather than an open‑market trade.
Following the grant, Walbert directly holds 17,270 shares of BioMarin common stock. In addition, 416 shares are reported as indirectly held through Prairie Capital Ventures LLC. The filing does not show any sales or option exercises, only this award and an updated indirect holding line.
BioMarin Pharmaceutical director Maykin Ho reported an equity grant of company stock. On June 2, 2026, Ho acquired 7,490 shares of BioMarin common stock through a grant classified as restricted stock units, with no cash price per share.
Following this award, Ho directly holds 35,500 shares of BioMarin common stock. Because this was a compensation-related grant rather than an open-market trade, it mainly reflects ongoing equity-based director compensation rather than a change in personal investment stance.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Robert J. Hombach received a new equity award in the form of restricted stock units. On June 2, 2026, he was granted 7,490 shares of Common Stock as a compensation award, with no purchase price applicable to the grant.
Following this award, Hombach directly holds 49,360 shares of BioMarin common stock. This is a non-market transaction classified as a grant or award, rather than an open-market share purchase or sale.
BioMarin Pharmaceutical director Mark J. Enyedy received a stock-based compensation award. On June 2, 2026, he acquired 7,490 shares of common stock through a grant of restricted stock units, with no cash price per share. After this award, he directly holds 21,040 common shares.